International Business News - Wyeth http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif A New Jersey-based drug maker is laying off more than 100 employees at the northern New York plant it has sold to another pharmaceutical company. Officials at Wyeth's plant in Rouses Point, on the Canadian border, said Tuesday 118 workers will be laid off in January because of declining demand for the drugs produced there. http://www.ibtimes.com/articles/20081119/wyeth-laying-off-118-workers-at-upstate-ny-plant.htm Wed, 19 Nov 2008 12:28:28 EST Wyeth said Thursday its hormone-replacing drug Premarin Vaginal Cream has been approved for a new use against pain experienced by postmenopausal women during sex. http://www.ibtimes.com/articles/20081113/fda-oks-wyeths-premarin-cream-for-new-use.htm Thu, 13 Nov 2008 16:46:05 EST Like many of the top pharmaceutical companies, Wyeth is narrowing its research focus to far fewer diseases as it tries to produce more successful new drugs, particularly for conditions lacking good treatments. http://www.ibtimes.com/articles/20081029/wyeth-latest-drugmaker-to-narrow-focus-of-research.htm Wed, 29 Oct 2008 17:30:09 EDT Drug developer Wyeth reported a slight drop in its third-quarter profit Wednesday but still managed to meet Wall Street forecasts as it continues with a restructuring program meant to shore up the company as generic competition cuts into profit. http://www.ibtimes.com/articles/20081022/wyeth-3q-profit-falls-but-meets-forecasts.htm Wed, 22 Oct 2008 11:23:15 EDT Drug developer Wyeth reports earnings for the third quarter on Wednesday morning. The following is a summary of key developments and analyst opinion related to the period. http://www.ibtimes.com/articles/20081021/earnings-preview-wyeth.htm Tue, 21 Oct 2008 10:26:35 EDT Drug developer Wyeth said Wednesday it will postpone pursuing regulatory approval for its antidepressant Pristiq in Europe and is conducting additional late-stage studies on the drug. http://www.ibtimes.com/articles/20081015/wyeth-postpones-seeking-pristiq-approval-in-europe.htm Wed, 15 Oct 2008 12:46:33 EDT Advanced Life Sciences Holdings Inc. and Wyeth said Wednesday they signed a contract to develop and sell the antibiotic cethromycin in the Asia Pacific region, excluding Japan. http://www.ibtimes.com/articles/20081001/advanced-life-sciences-wyeth-team-on-antibiotic.htm Wed, 01 Oct 2008 10:55:19 EDT Wyeth said late Thursday its board of directors boosted the drug developer's quarterly dividend by 7.1 percent, citing the company's cash position, receding litigation payments and growth prospects. http://www.ibtimes.com/articles/20080926/wyeth-board-increases-dividend-by-7-1-percent.htm Fri, 26 Sep 2008 07:22:01 EDT An experimental menopause treatment drugmaker Wyeth is developing reduced hot flashes, trouble sleeping and other symptoms and did not increase breast tenderness, a problem that bothers many women taking menopause drugs, according to data from two studies released Thursday. http://www.ibtimes.com/articles/20080925/wyeth-menopause-drug-reduces-multiple-symptoms.htm Thu, 25 Sep 2008 14:30:34 EDT Wyeth Consumer Healthcare, a division of pharmaceutical giant Wyeth, said it has completed the acquisition of the ThermaCare heat-wrap brand from Procter & Gamble Co. http://www.ibtimes.com/articles/20080902/wyeth-completes-acquisition-of-thermacare-from-p-g.htm Tue, 02 Sep 2008 16:22:23 EDT Wyeth on Thursday extended a partnership with drug developer Karo Bio of Sweden, through which the companies collaborate to develop drugs to treat the artery disease atherosclerosis. http://www.ibtimes.com/articles/20080814/wyeth-extends-atherosclerosis-partnership.htm Thu, 14 Aug 2008 08:08:29 EDT Wyeth spent more than $801,000 lobbying on prescription drug-related issues in the second quarter, according to a recent disclosure form. The drugmaker lobbied against efforts to allow the importation of cheaper prescription medicines from Canada and other foreign countries. Proponents said foreign competition would help drive down U.S. drug prices, but the pharmaceutical industry warned it could expose Americans to counterfeit medications. Efforts to pass an importation bill fizzled in Congress earlier this year, despite several hearings. http://www.ibtimes.com/articles/20080805/wyeth-spent-over-801k-lobbying-government-in-2q.htm Tue, 05 Aug 2008 14:04:01 EDT Among the premarket stories for Wednesday, July 28, from AP Financial News: NEW YORK (AP)--Shares of Wyeth and Elan Corp. PLC plunged in premarket trading Wednesday after analysts said new data on their Alzheimer's disease drug candidate bapineuzumab makes it less likely the drug will reach the market. http://www.ibtimes.com/articles/20080730/premarket-roundup-wyeth-elan-molson-coors.htm Wed, 30 Jul 2008 09:39:22 EDT Elan Corp. and its partner Wyeth are scheduled to present midstage study data on their Alzheimer's disease treatment Tuesday, possibly giving investors a glimpse of what a larger, late-stage study could yield. http://www.ibtimes.com/articles/20080728/ahead-of-the-bell-elan-wyeths-alzheimers-drug.htm Mon, 28 Jul 2008 08:51:06 EDT Shares of drug developer Wyeth rose in premarket trading Wednesday after the company posted strong second-quarter results, and forecast a full-year profit that is above analyst expectations. http://www.ibtimes.com/articles/20080723/ahead-of-the-bell-new-outlook-lifts-wyeth.htm Wed, 23 Jul 2008 08:44:13 EDT Wyeth said Wednesday its second-quarter profit fell 6.3 percent on charges for severance and other costs related to ongoing job cuts, but the drug developer still topped Wall Street expectations and raised its full-year outlook. http://www.ibtimes.com/articles/20080723/wyeth-2q-profit-falls-on-charges-for-job-cuts.htm Wed, 23 Jul 2008 19:11:50 EDT Wyeth, the world's No. 12 drug company by revenue, reports earnings for the second quarter on Wednesday morning. The following is a summary of key developments and analyst opinion related to the period. http://www.ibtimes.com/articles/20080722/flat-earnings-seen-for-drugmaker-wyeth.htm Tue, 22 Jul 2008 19:50:12 EDT Drug developer Wyeth said Wednesday a U.S. court approved a settlement with generic competitor Impax Laboratories, ending a patent lawsuit over an extended-release version of Wyeth's blockbuster antidepressant Effexor. http://www.ibtimes.com/articles/20080716/wyeth-settles-patent-dispute-with-impax.htm Wed, 16 Jul 2008 17:37:02 EDT Consumer goods company Procter & Gamble Co. agreed to sell its ThermaCare heat wrap business to a unit of drug maker Wyeth on Tuesday. The ThermaCare line includes six kinds of heat wraps, which treat muscle, joint and menstrual pain and minor arthritis pain. The business will be taken over by the Wyeth Consumer Healthcare unit. The companies did not disclose terms but said they expect the deal to close in the next few months. http://www.ibtimes.com/articles/20080715/wyeth-will-buy-thermacare-from-procter-gamble.htm Tue, 15 Jul 2008 15:13:34 EDT Drug developers Wyeth and Progenics Pharmaceuticals Inc. said Thursday European regulators approved Relistor as a treatment for constipation related to pain drugs taken by terminally ill patients. http://www.ibtimes.com/articles/20080703/wyeth-progenics-get-european-constipation-drug-ok.htm Thu, 03 Jul 2008 13:23:23 EDT